The Pharma Data

SEPTEMBER 16, 2020

Data will also be presented for two of our investigational hormone receptor (HR)-positive breast cancer treatments, both of which target the PI3K/AKT signalling pathway, a key driver of cancer cell growth and proliferation. HR-positive breast cancer. GDC-0077 is our next generation investigational PI3K? Ipatasertib. Lung cancer.

HR 52

HR Medicine Hormones Trials 52

The Pharma Data

MARCH 20, 2021

The vast majority of current laboratory testing for COVID-19 is based either on detection of viral antigens, nucleic acids or on detection of virus-specific antibodies in the sera of patients. Detection of virus-specific antibodies allows for diagnosis of recent symptomatic or even asymptomatic infections. SARS-CoV-2 proteome.

Protein 52

Protein Antibody Development RNA 52

The Pharma Data

SEPTEMBER 2, 2021

Transforming treatment of advanced cancers with antibody drug conjugates (ADCs). Antibody drug conjugates. A Phase 2 Study of Datopotamab Deruxtecan (Dato-DXd) in Advanced NSCLC With Actionable Genomic Alterations (TROPION-Lung05). Antibody drug conjugates. Abstract #P47.11. 8 September 2021. Borghaei, H. Johnson, ML.

Trials 52

Trials Medicine Antibody Clinical Trials 52

The Pharma Data

MARCH 26, 2021

months; hazard ratio [HR]=0.59, 95% CI: 0.40–0.89; months (HR=0.76, 95% CI: 0.54–1.09). Tecentriq is a monoclonal antibody designed to bind with a protein called Programmed Death Ligand-1 (PD-L1), which is expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1

HR 52

HR Protein Genome Genomics 52

The Pharma Data

MAY 4, 2021

months; hazard ratio [HR]=0.59, 95% CI: 0.40–0.89; months (HR=0.76, 95% CI: 0.54–1.09). About Tecentriq Tecentriq is a monoclonal antibody designed to bind with a protein called Programmed Death Ligand-1 (PD-L1), which is expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1

HR 52

HR Protein In-Vitro Medicine 52

The Pharma Data

MARCH 23, 2021

For OS and PFS, KEYTRUDA plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; 0.86]; p<0.0001) and reduced the risk of disease progression or death by 35% (HR=0.65 [95% CI, 0.55-0.76]; for the placebo arm, with a HR of 0.62 (95% CI, 0.49-0.78; for the placebo arm, with a HR of 0.86 (95% CI, 0.68-1.10).

HR 52

HR FDA Approval Containment Genome 52

The Pharma Data

JANUARY 4, 2021

Food and Drug Administration (FDA) , in combination with Tecentriq ® (atezolizumab) for the first-line treatment of people with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression with no EGFR or ALK genomic tumor aberrations. months with Tecentriq alone; HR=0.30, 95% CI: 0.15–0.61). About tiragolumab.

Immune Response 52

Immune Response Medicine Protein Gene 52